​Pharmacology - Enoxaparin

​Pharmacology - Enoxaparin 
This prevents the blood from coagulating.

Method of Operation 
Antithrombin III (ATIII) is able to accelerate its action, which in turn increases its ability to inactivate Factor Xa.

injected through a subcutaneous space. The elimination half-life is between 130 and 180 minutes; renal excretion.

Use in Clinical Settings
in order to avoid any venous thromboembolism.
Deep vein thrombosis, pulmonary embolism, myocardial infarction, and unstable angina are to be treated with this medication.

Mode of Action 
Blood loss is the primary adverse impact. Less prone to produce thrombocytopenia, hypersensitivity reactions, and osteoporosis than heparin and other similar medications.

Activated partial thromboplastin time does not need to be monitored at this time. To treat an overdose, protamine sulfate was administered.